Your activity: 2 p.v.

Mosunetuzumab: Drug information

Mosunetuzumab: Drug information
For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Cytokine release syndrome:

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving mosunetuzumab. Initiate treatment with the mosunetuzumab step-up dosing schedule to reduce the risk of CRS. Withhold mosunetuzumab until CRS resolves or permanently discontinue based on severity.

Pharmacologic Category
  • Antineoplastic Agent, Anti-CD3;
  • Antineoplastic Agent, Bispecific T Cell Engager;
  • Antineoplastic Agent, Monoclonal Antibody
Product Availability

Lunsumio: FDA approved December 2022; anticipated availability currently unknown.

Use: Labeled Indications

Follicular lymphoma: Treatment of relapsed or refractory follicular lymphoma in adults after ≥2 lines of systemic therapy.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.


Cardiovascular: Edema (17%)

Dermatologic: Pruritus (21%), skin rash (39%), xeroderma (16%)

Endocrine & metabolic: Decreased serum magnesium (34%), decreased serum phosphate (78%), decreased serum potassium (33%), increased serum glucose (42%), increased uric acid (22%)

Gastrointestinal: Abdominal pain (12%), diarrhea (17%), nausea (17%)

Hematologic & oncologic: Decreased hemoglobin (68%; grades 3/4: 12%), decreased neutrophils (58%; grades 3/4: 40%), decreased white blood cell count (60%; grades 3/4: 13%), lymphocytopenia (100%; grades 3/4: 98%), thrombocytopenia (46%; grades 3/4: 10%)

Hepatic: Increased gamma-glutamyl transferase (34%), increased serum alanine aminotransferase (32%), increased serum aspartate aminotransferase (39%)

Hypersensitivity: Cytokine release syndrome (44%)

Nervous system: Chills (13%), dizziness (12%), fatigue (42%), headache (32%), insomnia (12%), peripheral neuropathy (20%)

Neuromuscular & skeletal: Arthralgia (11%), musculoskeletal pain (28%)

Respiratory: Cough (22%), dyspnea (11%), upper respiratory tract infection (14%)

Miscellaneous: Fever (29%)

1% to 10%:

Dermatologic: Desquamation (10%)

Genitourinary: Urinary tract infection (10%)

Hematologic & oncologic: Tumor flare (<10%), tumor lysis syndrome (<10%)

Infection: Epstein-Barr infection (<10%), sepsis (<10%)

Nervous system: Anxiety (<10%), mental status changes (<10%; including cognitive dysfunction, confusion, delirium, disturbance in attention, drowsiness, encephalopathy), motor dysfunction (<10%; including abnormal gait, ataxia, tremor)

Renal: Renal insufficiency (<10%)

Respiratory: Pneumonia (<10%)

Frequency not defined:

Hematologic & oncologic: Febrile neutropenia

Infection: Serious infection (including opportunistic infection)

Nervous system: Neurotoxicity (including immune effector cell-associated neurotoxicity syndrome)


There are no contraindications listed in the manufacturer's labeling.

  1. Lunsumio (mosunetuzumab) [prescribing information]. South San Francisco, CA: Genentech, Inc; December 2022.
Topic 140391 Version 2.0